Mental Health Companies With FDA Indications: A Psychiatrist’s Guide

Written by Healing Sky Editorial Team. Clinically reviewed by Raul Rodriguez M.D.

Patients and families often ask a version of the same question: "What are the newest non-medication mental health treatments that have an FDA indication?" Several exist, but "FDA indication" can mean different things depending on whether the product is a drug, a medical device like transcranial magnetic stimulation (TMS), or a prescription digital therapeutic delivered on a phone or watch. Knowing which companies truly hold an FDA-indicated treatment, and what that indication actually covers, helps patients choose safe, effective options and avoid misleading claims.

This guide explains what an FDA indication means in mental health, why it matters, and which companies currently offer FDA-indicated treatments across medications, devices, and digital therapeutics. It also includes a checklist for verifying any company's claims and practical guidance on how to use this information in your care.

What "FDA Indication" Really Means

When a company is said to "have an FDA indication," it means a specific product from that company has been reviewed by the U.S. Food and Drug Administration and authorized for a defined use. In mental health, that authorization can take several forms: FDA approval for medications (for example, esketamine for treatment-resistant depression); FDA clearance or authorization for devices (for example, TMS systems for depression and OCD, or vagus nerve stimulation for treatment-resistant depression); and De Novo classification or 510(k) clearance for novel or predicate devices, including many prescription digital therapeutics.

Three concepts are essential to understand. The indication specifies the exact diagnosis, symptom domain, age range, and how the product must be used, for example, "adjunctive treatment," "in combination with an oral antidepressant," or "prescription only." The labeling contains the official instructions for use, benefits, and risks, and is what insurers and clinicians rely on. The on-label vs. off-label distinction matters because clinicians can legally prescribe many treatments off-label, but payers and clinical programs often require on-label use.

Why an FDA Indication Matters for Your Care

FDA review weighs benefits against risks for the exact population described on the label, which is why the indication matters for safety and effectiveness. The indication also provides clarity: it tells patients who the product helps, how it should be given, and which warnings apply, for example, sedation monitoring requirements or REMS programs. From an access standpoint, insurers, health systems, and employers are more likely to cover or contract for products with clear, specific FDA indications. An indication also anchors post-market surveillance, quality controls, and truthful marketing requirements.

FDA-indicated Options Across Categories

The sections below cover examples of companies with products that hold an FDA indication in mental health, grouped by treatment type.

FDA-approved Medications

Johnson & Johnson (Janssen): Spravato (esketamine) nasal spray

Spravato is indicated for adults with treatment-resistant depression (TRD), as well as for depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior (with an oral antidepressant). As of January 21, 2025, the FDA approved SPRAVATO for use as monotherapy for adults with TRD, with or without a concomitant oral antidepressant. Treatment takes place in certified clinics under an FDA-mandated REMS program, with observation required after each dose. (investor.jnj.com)

Sage Therapeutics (with Biogen): Zurzuvae (zuranolone)

In August 2023, the FDA approved Zurzuvae (zuranolone) as the first oral medication specifically indicated for postpartum depression (PPD) in adults. It is taken once daily for 14 days and carries driving and sedation precautions on the label. (fda.gov)

Both medications are indicated for defined populations and include safety programs or monitoring requirements. Coverage often requires prior authorization and on-label use. Rapid symptom relief is possible with either, but ongoing support, therapy, safety planning, family involvement, remains essential.

Noninvasive Neuromodulation Devices (TMS)

Transcranial magnetic stimulation is an office-based, noninvasive brain-stimulation therapy for mood and related conditions. Multiple companies hold FDA-indicated TMS devices.

Neuronetics: NeuroStar TMS

NeuroStar was the first FDA-cleared TMS system for adults with major depressive disorder, cleared in 2008. In March 2024, Neuronetics received FDA clearance for NeuroStar as a first-line, adjunct treatment for adolescents aged 15 to 21 with MDD. (510k.innolitics.com) (ir.neuronetics.com)

BrainsWay: Deep TMS

BrainsWay's Deep TMS system is FDA-cleared for major depressive disorder (2013), obsessive-compulsive disorder (2018), aid in short-term smoking cessation (2020), and decreasing comorbid anxiety symptoms in MDD, sometimes called "anxious depression" (2021). The H-coil design is intended to stimulate deeper brain regions than standard coils. (brainsway.com) (brainsway.com)

Magnus Medical: SAINT Neuromodulation System

The SAINT system received 510(k) clearance in 2022 for adults with major depressive disorder who have not responded adequately to antidepressants. It implements a personalized, accelerated intermittent theta-burst (iTBS) protocol guided by MRI, and many clinical programs deliver accelerated courses over five days. (magnusmedical.com)

TMS is noninvasive and medication-free and can be considered when previous antidepressant trials have failed or caused intolerable side effects. Protocols vary, daily sessions over several weeks versus accelerated five-day courses, and insurance coverage depends on diagnosis, number of prior medication trials, and the specific device and protocol. Before pursuing TMS, it is worth discussing with a clinician whether the depression has met criteria for treatment-resistant depression, which TMS system is available locally and for which indications, and practical factors such as session length, total number of visits, and likelihood of coverage.

Implantable Neuromodulation

LivaNova: Vagus Nerve Stimulation (VNS) Therapy

VNS Therapy received FDA approval (PMA supplement) in July 2005 as an adjunctive, long-term treatment for chronic or recurrent depression in adults who have not responded adequately to four or more antidepressant treatments in the current episode. It is an implanted system with surgical and maintenance considerations, and coverage policies vary. (fda.report)

VNS is typically considered after multiple failed or poorly tolerated medication and therapy trials, particularly when a durable, maintenance-oriented option is desired. Patients must be comfortable with surgical implantation and the follow-up programming process.

Prescription Digital Therapeutics and Other Regulated Digital Treatments

Digital therapeutics, software classified as a medical device, can hold FDA indications just like other devices. Several companies have FDA-authorized products for specific mental health conditions.

Akili Interactive

EndeavorRx is the first FDA-authorized prescription video game-based treatment to improve attention function as measured by computer-based testing in pediatric ADHD. Originally authorized in 2020 for ages 8 to 12, the label was expanded in December 2023 to include ages 13 to 17, making the pediatric range 8 to 17. In June 2024, Akili announced FDA authorization for EndeavorOTC, an over-the-counter product for adults with ADHD and the first FDA-authorized OTC digital ADHD treatment. (akiliinteractive.com) (Form 8-K / company filings) (advfn.com)

NightWare

The FDA permitted marketing of NightWare in November 2020 for the temporary reduction of sleep disturbance due to nightmares in adults 22 years of age or older who have nightmare disorder or PTSD-related nightmares. NightWare uses an Apple Watch to detect physiologic signals and deliver gentle vibrations. It is prescription-only and intended to be part of broader PTSD care. (aasm.org) (prnewswire.com)

Freespira (capnometry-guided respiratory intervention)

Freespira was FDA-cleared for panic disorder and later cleared for PTSD in December 2018. In May 2025, the company announced FDA 510(k) clearance extending indications to adolescents ages 13 to 17. Freespira pairs a sensor-guided breathing protocol with remote coaching over four weeks. (freespira.com)

Somryst (digital CBT-I)

Somryst was authorized by the FDA in March 2020 as the first prescription digital therapeutic cleared for chronic insomnia in adults. After Pear Therapeutics filed for Chapter 11 in 2023 and sold assets, Nox Health acquired Somryst and has been integrating it into sleep-care programs. (businesswire.com)

These are regulated medical products with specific indications and instructions, very different from wellness apps. Coverage varies; some are prescription-only, while others (like EndeavorOTC) are authorized for over-the-counter use. Best results come when they are integrated into a comprehensive treatment plan.

Off-label Care vs. FDA-indicated Options

Ketamine infusions for depression are commonly used off-label in clinics. Ketamine is FDA-approved as an anesthetic but is not FDA-approved for psychiatric disorders, which often limits insurance coverage and standardization. Esketamine (Spravato), by contrast, is FDA-approved and REMS-regulated for specific depressive indications and must be given in certified clinics with observation. As noted above, SPRAVATO gained an FDA monotherapy indication for TRD on January 21, 2025. (investor.jnj.com)

Off-label treatment can still be appropriate, but an FDA-indicated option usually offers clearer evidence standards, monitoring requirements, and a pathway to coverage.

How to Verify Whether a Company Truly Has an FDA Indication

Before committing time or money, take 10 minutes to confirm the facts.

• Read the indication statement. Look for the diagnosis (for example, MDD, OCD, PTSD, or insomnia), age range, and whether the product is "adjunctive," "prescription-only," or requires monitoring.
• Check the official labeling and instructions for use. Companies that are FDA-authorized display "Important Safety Information" and specific, consistent language about use, contraindications, and risks.
• Search the FDA device databases. Many devices and digital therapeutics appear in 510(k), De Novo, or PMA listings with their indication and date of clearance or authorization.
• Distinguish marketing terms from regulatory status. "FDA registered" or "compliant" is not the same as "FDA-cleared," "FDA-authorized," or "FDA-approved."
• Ask the company directly. Request the product's exact FDA indication and the authorization pathway (approval, clearance, De Novo) in writing.

Questions to ask a prospective clinic or vendor:

• Is the treatment on-label for my diagnosis and age?
• What evidence supports benefits for people with my profile, and what are the common side effects?
• What does a full course of care involve, visits, coaching, or monitoring?
• How will progress be measured, and how will decisions about continuing be made?
• Will my health plan cover it? If not, what are the total costs and alternatives?

Matching the Right FDA-indicated Option to Your Needs

Choosing among medications, neuromodulation, and digital therapeutics depends on goals, history, and preferences. The options below are starting points for a conversation with a clinician, not substitutes for one.

• If you've tried multiple antidepressants without relief: Consider TMS (standard or accelerated) or esketamine in a REMS-certified clinic. If depression is longstanding and highly resistant, discuss VNS with a psychiatrist.
• If PTSD-related nightmares dominate your sleep: A prescription for NightWare may help reduce awakenings as part of a broader trauma-focused plan. (prnewswire.com)
• If panic attacks or hyperventilation drive your anxiety: Freespira's structured breathing program with coaching may be a fit. (freespira.com)
• If insomnia undermines daytime functioning: Digital CBT-I through an FDA-cleared program like Somryst can be an evidence-based alternative or complement to therapy. (businesswire.com)
• If attention is the main barrier: For children and teens, a prescription for EndeavorRx may help improve attention function; for adults, EndeavorOTC is authorized for over-the-counter use. (akiliinteractive.com)

Sequencing treatments thoughtfully, rather than trying many at once, makes it easier to identify what is actually helping.

How Healing Sky Can Help

Healing Sky connects patients with professionals who begin with a careful diagnostic review, treatment history, and stated goals, then map options that fit, including FDA-indicated choices where appropriate. That may mean recommending an on-label device or medication after standard therapies have been tried, integrating digital therapeutics into a broader plan that includes therapy, lifestyle support, and symptom tracking, or helping navigate coverage, prior authorizations, and certified treatment settings.

If a company's claim seems unclear, or the right option is hard to identify, bring the details to a Healing Sky professional. They will translate the label into clear next steps.

(investor.jnj.com)